EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer: Efficacy and Safety Data

Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers in highlighting the efficacy and safety data from the EMERALD trial and identifying appropriate use of elacestrant in patients with ER+, HER2- advanced breast cancer.

EP: 1.Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer

Now Viewing

EP: 2.EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer: Efficacy and Safety Data

EP: 3.ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial

Related Videos